vs
Side-by-side financial comparison of Celanese Corp (CE) and Quest Diagnostics (DGX). Click either name above to swap in a different company.
Quest Diagnostics is the larger business by last-quarter revenue ($2.9B vs $2.2B, roughly 1.3× Celanese Corp). Quest Diagnostics runs the higher net margin — 9.7% vs 0.6%, a 9.1% gap on every dollar of revenue. On growth, Quest Diagnostics posted the faster year-over-year revenue change (9.2% vs -7.0%). Over the past eight quarters, Quest Diagnostics's revenue compounded faster (9.9% CAGR vs -8.1%).
Celanese Corporation, formerly known as Hoechst Celanese, is an American technology and specialty materials company headquartered in Irving, Texas. It is a Fortune 500 corporation. The company is the world's leading producer of acetic acid, producing about 1.95 million tonnes per year, representing approximately 20% of global production. Celanese is also the world's largest producer of vinyl acetate monomer (VAM).
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
CE vs DGX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.2B | $2.9B |
| Net Profit | $14.0M | $281.0M |
| Gross Margin | 19.1% | — |
| Operating Margin | 4.0% | 15.4% |
| Net Margin | 0.6% | 9.7% |
| Revenue YoY | -7.0% | 9.2% |
| Net Profit YoY | 100.7% | 12.0% |
| EPS (diluted) | $0.13 | $2.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.9B | ||
| Q4 25 | $2.2B | $2.8B | ||
| Q3 25 | $2.4B | $2.8B | ||
| Q2 25 | $2.5B | $2.8B | ||
| Q1 25 | $2.4B | $2.7B | ||
| Q4 24 | $2.4B | $2.6B | ||
| Q3 24 | $2.6B | $2.5B | ||
| Q2 24 | $2.7B | $2.4B |
| Q1 26 | — | $281.0M | ||
| Q4 25 | $14.0M | $245.0M | ||
| Q3 25 | $-1.4B | $245.0M | ||
| Q2 25 | $199.0M | $282.0M | ||
| Q1 25 | $-21.0M | $220.0M | ||
| Q4 24 | $-1.9B | $222.0M | ||
| Q3 24 | $116.0M | $226.0M | ||
| Q2 24 | $155.0M | $229.0M |
| Q1 26 | — | — | ||
| Q4 25 | 19.1% | 32.4% | ||
| Q3 25 | 21.5% | 33.7% | ||
| Q2 25 | 21.1% | 34.2% | ||
| Q1 25 | 19.9% | 32.5% | ||
| Q4 24 | 22.7% | 32.7% | ||
| Q3 24 | 23.5% | 32.6% | ||
| Q2 24 | 24.2% | 33.5% |
| Q1 26 | — | 15.4% | ||
| Q4 25 | 4.0% | 13.8% | ||
| Q3 25 | -52.7% | 13.7% | ||
| Q2 25 | 9.2% | 15.9% | ||
| Q1 25 | 7.0% | 13.0% | ||
| Q4 24 | -59.3% | 13.8% | ||
| Q3 24 | 9.4% | 13.3% | ||
| Q2 24 | 9.4% | 14.8% |
| Q1 26 | — | 9.7% | ||
| Q4 25 | 0.6% | 8.7% | ||
| Q3 25 | -56.1% | 8.7% | ||
| Q2 25 | 7.9% | 10.2% | ||
| Q1 25 | -0.9% | 8.3% | ||
| Q4 24 | -80.8% | 8.5% | ||
| Q3 24 | 4.4% | 9.1% | ||
| Q2 24 | 5.8% | 9.6% |
| Q1 26 | — | $2.24 | ||
| Q4 25 | $0.13 | $2.18 | ||
| Q3 25 | $-12.39 | $2.16 | ||
| Q2 25 | $1.81 | $2.47 | ||
| Q1 25 | $-0.19 | $1.94 | ||
| Q4 24 | $-17.50 | $1.95 | ||
| Q3 24 | $1.06 | $1.99 | ||
| Q2 24 | $1.41 | $2.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $393.0M |
| Total DebtLower is stronger | $11.4B | $5.7B |
| Stockholders' EquityBook value | $4.0B | $7.7B |
| Total Assets | $21.7B | $16.7B |
| Debt / EquityLower = less leverage | 2.81× | 0.74× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $393.0M | ||
| Q4 25 | — | $420.0M | ||
| Q3 25 | — | $432.0M | ||
| Q2 25 | — | $319.0M | ||
| Q1 25 | — | $188.0M | ||
| Q4 24 | — | $549.0M | ||
| Q3 24 | — | $764.0M | ||
| Q2 24 | — | $271.0M |
| Q1 26 | — | $5.7B | ||
| Q4 25 | $11.4B | $5.2B | ||
| Q3 25 | $11.7B | $5.2B | ||
| Q2 25 | $12.7B | $5.2B | ||
| Q1 25 | $12.4B | $5.9B | ||
| Q4 24 | $11.1B | $5.6B | ||
| Q3 24 | $11.3B | $5.6B | ||
| Q2 24 | $11.1B | $3.8B |
| Q1 26 | — | $7.7B | ||
| Q4 25 | $4.0B | $7.2B | ||
| Q3 25 | $4.0B | $7.3B | ||
| Q2 25 | $5.3B | $7.2B | ||
| Q1 25 | $5.2B | $6.9B | ||
| Q4 24 | $5.2B | $6.8B | ||
| Q3 24 | $7.3B | $6.8B | ||
| Q2 24 | $7.2B | $6.6B |
| Q1 26 | — | $16.7B | ||
| Q4 25 | $21.7B | $16.2B | ||
| Q3 25 | $22.2B | $16.2B | ||
| Q2 25 | $23.7B | $16.0B | ||
| Q1 25 | $23.2B | $15.8B | ||
| Q4 24 | $22.9B | $16.2B | ||
| Q3 24 | $25.9B | $16.1B | ||
| Q2 24 | $25.8B | $13.9B |
| Q1 26 | — | 0.74× | ||
| Q4 25 | 2.81× | 0.72× | ||
| Q3 25 | 2.95× | 0.71× | ||
| Q2 25 | 2.41× | 0.72× | ||
| Q1 25 | 2.39× | 0.85× | ||
| Q4 24 | 2.14× | 0.83× | ||
| Q3 24 | 1.56× | 0.83× | ||
| Q2 24 | 1.54× | 0.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $252.0M | $278.0M |
| Free Cash FlowOCF − Capex | $168.0M | — |
| FCF MarginFCF / Revenue | 7.6% | — |
| Capex IntensityCapex / Revenue | 3.8% | 3.9% |
| Cash ConversionOCF / Net Profit | 18.00× | 0.99× |
| TTM Free Cash FlowTrailing 4 quarters | $803.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $278.0M | ||
| Q4 25 | $252.0M | $465.0M | ||
| Q3 25 | $447.0M | $563.0M | ||
| Q2 25 | $410.0M | $544.0M | ||
| Q1 25 | $37.0M | $314.0M | ||
| Q4 24 | $494.0M | $464.0M | ||
| Q3 24 | $79.0M | $356.0M | ||
| Q2 24 | $292.0M | $360.0M |
| Q1 26 | — | — | ||
| Q4 25 | $168.0M | $307.0M | ||
| Q3 25 | $383.0M | $419.0M | ||
| Q2 25 | $317.0M | $436.0M | ||
| Q1 25 | $-65.0M | $197.0M | ||
| Q4 24 | $389.0M | $341.0M | ||
| Q3 24 | $-9.0M | $250.0M | ||
| Q2 24 | $187.0M | $268.0M |
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 10.9% | ||
| Q3 25 | 15.8% | 14.9% | ||
| Q2 25 | 12.5% | 15.8% | ||
| Q1 25 | -2.7% | 7.4% | ||
| Q4 24 | 16.4% | 13.0% | ||
| Q3 24 | -0.3% | 10.0% | ||
| Q2 24 | 7.1% | 11.2% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 3.8% | 5.6% | ||
| Q3 25 | 2.6% | 5.1% | ||
| Q2 25 | 3.7% | 3.9% | ||
| Q1 25 | 4.3% | 4.4% | ||
| Q4 24 | 4.4% | 4.7% | ||
| Q3 24 | 3.3% | 4.3% | ||
| Q2 24 | 4.0% | 3.8% |
| Q1 26 | — | 0.99× | ||
| Q4 25 | 18.00× | 1.90× | ||
| Q3 25 | — | 2.30× | ||
| Q2 25 | 2.06× | 1.93× | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | 2.09× | ||
| Q3 24 | 0.68× | 1.58× | ||
| Q2 24 | 1.88× | 1.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CE
| Engineered Materials | $1.3B | 58% |
| Acetyl Chain | $940.0M | 43% |
DGX
Segment breakdown not available.
